At its units in SEZ Indore (Pithampur) and Piparia (Silvassa)
Ipca Laboratories announced that it has received a communication from USFDA stating that all the drugs manufactured from the Company's manufacturing units situated at SEZ Indore (Pithampur) and Piparia (Silvassa) will be henceforth refused admission into the United States until the Company can demonstrate that the drugs manufactured sites and intended for the US market are in compliance with cGMP.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
